前列腺癌种族差异:前列腺癌基金会专家组的系统综述
该综述系统检索2011至2021年间3333篇文献,最终纳入52篇,并补充13篇筛选指南、临床试验及统计方法学文章,从人群层面综合前列腺癌差异证据。美国黑人男性前列腺癌发病率约为白人男性的1.8倍,差异源于社会经济因素与遗传背景的复杂交互;仅实现治疗后相似结局仍会因发病率负担不同而残留差异。综述强调需开展种族多样性研究并采用中介分析等新方法。
要点
- 美国黑人男性前列腺癌发病率约为白人男性的1.8倍。
- 差异源于社会经济因素与遗传因素的复杂交互作用。
- 需开展种族多样性研究并采用中介分析等新方法。
核心结论
- 前列腺癌种族差异是社会经济因素与遗传因素复杂交互的结果,需开展种族多样性研究以阐明机制。
研究设计与样本
- 采用系统文献综述方法和PRISMA流程,检索2011至2021年间3333篇文献,纳入52篇,另补充13篇筛选指南、临床试验及统计方法学文章。
主要发现
- 美国黑人男性前列腺癌人群发病率约为白人男性的1.8倍。
- 即使初级治疗后结局相似,未考虑种族特异性发病负担仍会导致残留差异和更高的长期死亡负担。
- 前列腺癌研究可能存在选择偏倚,因常依赖医疗资源使用较高的黑人男性队列。
关键数值与推荐
- 美国黑人男性前列腺癌发病率约为白人男性的1.8倍。
临床怎么用
- 应开展种族多样性研究,包括精准组学、预防和靶向治疗,以阐明种族差异机制。
- 可采用中介分析和遗传祖先而非自我认同种族来优化差异分析模型。
局限性
- 前列腺癌研究可能存在选择偏倚,常依赖医疗资源使用较高的黑人男性队列,可能不代表美国平均黑人患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Prostate cancer (PCa) is a complex disease that disproportionately impacts Black men in the USA. The structural factors that drive heterogeneous outcomes for patients of differing backgrounds are probably the same ones that result in population-level disparities. The relative contribution of drivers along the PCa disease continuum is an active area of investigation and debate. OBJECTIVE: To critically synthesize the available evidence on PCa disparities from a population-level perspective in comparison to data from "equal access and equal care settings" and to provide a consensus summary of the state of PCa disparities. EVIDENCE ACQUISITION: A plenary panel on PCa disparities presented at the Prostate Cancer Foundation meeting on October 24, 2019 and ensuing discussions are reported here. We used a systematic literature review approach and the Preferred Reporting Items for Systematic Reviews and Meta-analyses to select the most relevant publications. A total of 3333 publications between 2011 and 2021 were retrieved, of which 52 were included in the review; an additional 13 articles on screening guidelines, seminal clinical trials, and statistical methodology were used in the evidence synthesis. EVIDENCE SYNTHESIS: Race disparities in PCa are a result of a complex interaction between socioeconomic factors impacting access to care and ancestral/genetic factors that may influence tumor biology. Black men in the USA continue to have a nearly 1.8 times higher population-level incidence rate than White men. Failure to account for the race-specific incidence burden would continue to lead to residual disparity even after achieving relatively similar outcomes after primary treatment, resulting in a higher long-term mortality burden. Selection bias remains possible in PCa studies, which often rely on highly specific cohorts of Black men with higher use of health care resources that may not represent the average Black patient in the USA. Novel methods including mediation analysis and genetic ancestry rather than self-identified race can optimize analytical models investigating racial disparities and may lead to a better understanding of PCa genomic diversity and behavior. CONCLUSIONS: Our findings emphasize the importance of racially diverse studies, including precision -omics, prevention, and targeted therapy initiatives, to elucidate mechanisms underlying racial differences in outcomes and response to therapy. We propose novel approaches for studying and addressing PCa disparities. Contemporary methods, particularly in the domain of mediation analysis, can promote scientific rigor in understanding these disparities. PATIENT SUMMARY: Inaccurate data interpretation or lack of data altogether for Black men can impact policy and ultimately affect millions of individuals of African origin worldwide. Our review identifies a need to develop and prioritize a strategy for including Black and other men with prostate cancer in intervention studies and randomized clinical trials to halt the widening prostate cancer disparities.
引用
- Mahal BA, Gerke T, Awasthi S, et al. Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel. Eur Urol Oncol. 2021. PMID: 34446369. doi:10.1016/j.euo.2021.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。